ALLOGENE THERAPEUTICS INC (ALLO) Fundamental Analysis & Valuation

NASDAQ:ALLO • US0197701065

Current stock price

2.31 USD
-0.04 (-1.7%)
At close:
2.295 USD
-0.02 (-0.65%)
Pre-Market:

This ALLO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALLO Profitability Analysis

1.1 Basic Checks

  • ALLO had negative earnings in the past year.
  • In the past year ALLO has reported a negative cash flow from operations.
  • In the past 5 years ALLO always reported negative net income.
  • ALLO had a negative operating cash flow in each of the past 5 years.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -45.90%, ALLO perfoms like the industry average, outperforming 49.32% of the companies in the same industry.
  • ALLO has a Return On Equity of -65.25%. This is comparable to the rest of the industry: ALLO outperforms 54.37% of its industry peers.
Industry RankSector Rank
ROA -45.9%
ROE -65.25%
ROIC N/A
ROA(3y)-47.92%
ROA(5y)-41.84%
ROE(3y)-63.38%
ROE(5y)-53.63%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • ALLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ALLO Health Analysis

2.1 Basic Checks

  • ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALLO has been increased compared to 1 year ago.
  • The number of shares outstanding for ALLO has been increased compared to 5 years ago.
  • There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ALLO has an Altman-Z score of -5.02. This is a bad value and indicates that ALLO is not financially healthy and even has some risk of bankruptcy.
  • ALLO's Altman-Z score of -5.02 is on the low side compared to the rest of the industry. ALLO is outperformed by 63.88% of its industry peers.
  • ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.02
ROIC/WACCN/A
WACC9.41%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

  • ALLO has a Current Ratio of 7.93. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
  • ALLO has a better Current ratio (7.93) than 71.26% of its industry peers.
  • ALLO has a Quick Ratio of 7.93. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
  • ALLO's Quick ratio of 7.93 is fine compared to the rest of the industry. ALLO outperforms 71.84% of its industry peers.
Industry RankSector Rank
Current Ratio 7.93
Quick Ratio 7.93
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALLO Growth Analysis

3.1 Past

  • ALLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.59%, which is quite impressive.
  • Looking at the last year, ALLO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 21.08% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.78%
EPS Next 2Y5.02%
EPS Next 3Y6.8%
EPS Next 5Y21.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALLO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.
  • Also next year ALLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.02%
EPS Next 3Y6.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALLO Dividend Analysis

5.1 Amount

  • ALLO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALLO Fundamentals: All Metrics, Ratios and Statistics

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (4/24/2026, 8:20:59 PM)

Premarket: 2.295 -0.02 (-0.65%)

2.31

-0.04 (-1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners48.61%
Inst Owner Change0.1%
Ins Owners6.2%
Ins Owner Change-0.41%
Market Cap563.13M
Revenue(TTM)N/A
Net Income(TTM)-190.89M
Analysts82.86
Price Target7.57 (227.71%)
Short Float %18.21%
Short Ratio4.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.76%
Min EPS beat(2)16.55%
Max EPS beat(2)22.96%
EPS beat(4)4
Avg EPS beat(4)15.58%
Min EPS beat(4)5.26%
Max EPS beat(4)22.96%
EPS beat(8)8
Avg EPS beat(8)11.86%
EPS beat(12)11
Avg EPS beat(12)11.25%
EPS beat(16)15
Avg EPS beat(16)10.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.47%
PT rev (3m)1.24%
EPS NQ rev (1m)0.47%
EPS NQ rev (3m)9.78%
EPS NY rev (1m)10.71%
EPS NY rev (3m)10.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.01%
Revenue NY rev (3m)-18.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.92
P/tB 1.92
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -45.9%
ROE -65.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.92%
ROA(5y)-41.84%
ROE(3y)-63.38%
ROE(5y)-53.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.93
Quick Ratio 7.93
Altman-Z -5.02
F-Score3
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)6.3%
Cap/Depr(5y)52.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.29%
EPS Next Y8.78%
EPS Next 2Y5.02%
EPS Next 3Y6.8%
EPS Next 5Y21.08%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.74%
EBIT Next 3Y-5.41%
EBIT Next 5Y11.42%
FCF growth 1Y25.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.49%
OCF growth 3YN/A
OCF growth 5YN/A

ALLOGENE THERAPEUTICS INC / ALLO Fundamental Analysis FAQ

What is the fundamental rating for ALLO stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALLO.


What is the valuation status of ALLOGENE THERAPEUTICS INC (ALLO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALLOGENE THERAPEUTICS INC (ALLO). This can be considered as Overvalued.


How profitable is ALLOGENE THERAPEUTICS INC (ALLO) stock?

ALLOGENE THERAPEUTICS INC (ALLO) has a profitability rating of 1 / 10.


What is the expected EPS growth for ALLOGENE THERAPEUTICS INC (ALLO) stock?

The Earnings per Share (EPS) of ALLOGENE THERAPEUTICS INC (ALLO) is expected to grow by 8.78% in the next year.